Skip to search formSkip to main contentSkip to account menu

SYN-004

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Recombinant Proteinsbeta-Lactamase

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Sa1839 - Orally Delivered Beta-Lactamase Prevents Gut Microbiome Dysbiosis Caused by IV and Oral Antibiotics and Mitigates Propagation of Antibiotic Resistance in Porcine and Canine Models
2018
2018
1337. SYN-004 (Ribaxamase) Protects the Gut Microbiome of Patients Treated With Ceftriaxone From Disruption and Reduces the Emergence of Antimicrobial Resistance
Abstract Background When β-lactam antibiotics are administered intravenously, a significant portion of each dose can be excreted… 
2017
2017
SYN-004 (ribaxamase) prevents New Onset Clostridium difficile Infection by Protecting the Integrity Gut Microbiome in a Phase 2b Study
Abstract Background Clostridium difficile infections (CDI) are an “urgent threat,” but there are no approved drugs or vaccines to… 
2017
2017
SYN-004 (ribaxamase) Protects the Diversity of the Gut Microbiome in Patients Receiving Intravenous Ceftriaxone Treatment
P R I M A R Y E N D P O I N T C O N C L U S I O N S The use of intravenous β-lactam antibiotics, including cephalosporins, are an… 
2017
2017
SYN-006, a Novel Carbapenemase, Intended to Protect the Gut Microbiome from Antibiotic-Mediated Damage May Also Reduce Propagation of Carbapenem-Resistant Pathogens
May Also Reduce Propagation of Carbapenem-Resistant Pathogens Michael Kaleko1, Christian Furlan Freguia1, Nur A. Hasan2, Poorani… 
2017
2017
Gut Antibiotic Inactivation by Β-Lactamases Is Intended to Prevent Microbiome Damage and Attenuate Antibiotic Resistance in Large Animal Models
Sheila Connelly1, Christian Furlan-Freguia1, Poorani Subramanian2, Nur A. Hasan2, Rita R. Colwell2, Michael Kaleko1 1Synthetic… 
2016
2016
Healthcare facility-Associated Clostridium difficile Infection in Hospitalized Patients Receiving Intravenous Beta-Lactam Antibiotics in the Veterans Affairs Healthcare System (VHA)
2016
2016
SYN-004, A NOVEL STRATEGY TO PROTECT THE GUT MICROBIOME FROM THE DELETERIOUS EFFECTS OF RESIDUAL IV β-LACTAM ANTIBIOTICS
SYN-004 is a clinical stage oral β-lactamase therapy for use with intravenous (IV) β-lactam antibiotics to preserve the gut… 
2015
2015
Tu2054 SYN-004, a Clinical Stage Oral Beta-Lactamase Therapy, Protects the Intestinal Microflora from Antibiotic-Mediated Damage in Humanized Pigs
2014
2014
270SYN-004, a Class A Beta-Lactamase Therapy for the Prevention of Antibiotic-Induced Disruption of Intestinal Microflora
Background. ß-lactam antibiotics that are excreted into the intestine can damage the microflora, which can lead to serious… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)